Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Spinal cord injury
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Preclinical/no trial
- ChEMBL record
- CHEMBL18772 ↗
- ChEMBL max phase
- 2 / 4 (development scale, not regulatory approval)
- Synonyms
- Quipazina; Quipazine; Quipazine maleate; MA-1291; NSC-758469
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
RatSpinal cord injuryComplete transectionSprague-DawleyMale and femalen = 48 neonatal rats, 12 per drug and surgery combination, sex…Intraperitoneal3.0 mg/kg, delivered in a single 50 microlitre injectionGiven acutely after transection, following a 30-minute incubator recovery perio…
Model: Acute complete mid-thoracic spinal cord transection (T4 to T7) performed with a microknife under visual guidance, with sham surgery controls; sacrocaudal sensory afferent stimulation was delivered as a brief tail pinch with forceps
Quipazine restored hindlimb movement frequency and alternating step frequency in acutely spinalised pups to levels seen in intact pups after tail pinch, indicating an additive effect of 5-HT2A receptor activation and sacrocaudal sensory stimulation. Movement quality was only partially restored: spi…
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.93. Machine-extracted fields require source verification.